Novel antiapoptotic effect of TBX15: overexpression of TBX15 reduces apoptosis in cancer cells

Abstract T-box genes regulate development processes, some of these genes having also a role in cell proliferation and survival. TBX15 is a T-box transcription factor that, recently, has been proposed as a marker in prostate cancer, but its function in carcinogenesis is unknown. Here the role of TBX15 in carcinogenesis was investigated using thyroid cancer cell lines. First, using western blot analysis, we show that the expression of TBX15 was altered in thyroid cancer cells lines with respect to normal thyroid cells. Transfection of thyroid cancer cells with TBX15, in the presence or absence of camptothecin as a cytotoxic agent, proved non effect of TBX15 in cell viability; but, it increased cell proliferation after 48 h of transfection (P 
Source: Apoptosis - Category: Molecular Biology Source Type: research

Related Links:

Authors: Wang Y, Xu F, Zhong JY, Lin X, Shan SK, Guo B, Zheng MH, Yuan LQ Abstract Exosomes are a type of extracellular vehicle, formed by budding cell membranes, containing proteins, DNA, and RNA. Concentrated cargoes from parent cells are enveloped in exosomes, which are cell specific and may have functions in the recipient cell, reflecting a novel physiological and pathological mechanism in disease development. As a transmitter, exosomes shuttle to different cells or tissues and mediate communications among these organelles. To date, several studies have demonstrated that exosomes play crucial roles in disease p...
Source: International Journal of Endocrinology - Category: Endocrinology Tags: Int J Endocrinol Source Type: research
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th. ERLEADA® i...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Publication date: Available online 1 May 2020Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): Roland Kotolloshi, Kimia Mirzakhani, Joana Ahlburg, Florian Kraft, Thanakorn Pungsrinont, Aria Baniahmad
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
AbstractIntroductionBreast cancer (BC) and lung cancer (LuC) are common malignancies. The survival of patients with metachronous second primary malignancy (MSPM) of BC and LuC after a first primary of BC and LuC remains unclear.MethodsData of patients with BC and LuC, with or without MSPM of BC and LuC, who were diagnosed from 2000 to 2014, were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The baseline characteristics of the different groups were compared using chi-square tests. The survival curves were compared using the log-rank test. Survival analysis was also performed in other malign...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Authors: Filippi L, Chiaravalloti A, Schillaci O, Cianni R, Bagni O Abstract Introduction: Theranostics is an emerging field in which diagnosis and specific targeted therapy are combined to achieve a personalized treatment approach to the patient. In nuclear medicine clinical practice, theranostics is often performed utilizing the same molecule labeled with two different radionuclides, one radionuclide for imaging and another for therapy.Areas covered: The authors review the clinical applications of different radiopharmaceuticals in the field of interest, including the well-established use of radioactive iodine in ...
Source: Expert Review of Medical Devices - Category: Medical Devices Tags: Expert Rev Med Devices Source Type: research
We report a recently diagnosed case of prostate cancer demonstrating diffuse 68Ga-PSMA expression in both the lobes of thyroid gland, which on further clinical and biochemical investigations was established as hypothyroidism.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
Conclusion68Ga-PSMA PET/CT appears to have added value in patients with RAI-refractory DTC, as it is able to detect various types of lesions, some of which were not picked up by18FDG PET/CT. Furthermore,68Ga-PSMA PET/CT might be used to identify patients eligible for treatment with177Lu-PSMA-617. One of the two patients who underwent177Lu-PSMA-617 therapy showed a modest, temporary response. To draw conclusions about the effectiveness of this therapy, more research is needed.
Source: EJNMMI Research - Category: Radiology Source Type: research
Abstract Hypothyroidism is a common adverse event of lenvatinib therapy for hepatocellular carcinoma (HCC), whereas thyrotoxicosis has rarely been reported in clinical trials. A 74-year-old man complaining of abdominal pain was found to have liver tumors and paraaortic lymphadenopathy. The intrahepatic lesions were diagnosed as HCC by angiography and treated with transcatheter arterial chemoembolization. Although localized prostate cancer was discovered incidentally, the etiology of paraaortic lymphadenopathy was assumed to be metastatic HCC. Lenvatinib 12 mg/day was started when his thyroid function tests we...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin J Gastroenterol Source Type: research
(Physicians Committee for Responsible Medicine) Nutrition researcher and New York Times bestselling author Neal Barnard, MD, demonstrates how foods affect our hormones--and our health--in his new book, Your Body in Balance. Dr. Barnard shares the science behind how common conditions--like infertility, weight gain, menopausal symptoms, breast and prostate cancers, thyroid problems, and acne--are fueled by hormones that are hidden in or influenced by the foods we eat.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Abstract Bones are the third most common site for cancer metastases, and the axial skeleton is the most frequent skeletal location. In a postmortem study, bone metastases were reported in 70% of breast and prostate cancer patients. Bone metastases from breast, lung, prostate, thyroid, and kidney cancers account for 80% of all bone metastases. Bone lesions exist in 60% of newly diagnosed multiple myeloma patients. With increasing numbers of people who have survived cancer, many patients with cancer and axial skeletal bony metastases will be seen by physical and occupational therapists. Guidelines are lacking on how...
Source: Physical Therapy - Category: Physiotherapy Authors: Tags: Phys Ther Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Molecular Biology | Prostate Cancer | Thyroid | Thyroid Cancer